Fluoroscopy Time as a New Predictor of Short-Term Outcomes after Transcatheter Aortic Valve Replacement.
Valve Academic Research Consortium
aortic stenosis
device success
early safety
fluoroscopy
technical success
transcatheter aortic valve replacement
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
30
06
2023
revised:
23
10
2023
accepted:
26
10
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Transcatheter aortic valve replacement (TAVR) is an almost totally cine-fluoroscopic guided procedure. The amount of radiation used during the procedure is strictly related to the fluoroscopy time (FT), that has already been demonstrated to be associated with outcomes and complexity of coronary procedures. The aim of our study is to demonstrate the relationship between FT and the short-term outcomes after TAVR defined by to the Valve Academic Research Consortium (VARC)-2 and -3 consensus documents. After splitting 1797 consecutive patients into tertiles of FT, the composite endpoint early safety (ES) was adjudicated according to VARC-2 and VARC-3 definitions, whereas the composite endpoints device success (DS) and technical success (TS) according to VARC-3 criteria. The absence of all these outcomes (VARC-2 ES amd VARC-3 TS, DS, and ES) was significantly associated with longer FT: this association was independent from both intraprocedural complications and other intraprocedural factors linked to longer FT, and still persisted after propensity score matching analysis. Notwithstanding, after receiver operating characteristic analysis, FT had adequate diagnostic accuracy in identifying the absence of only VARC-3 TS and VARC-2 ES. Longer FT is related with periprocedural and short-term outcomes after the procedure, especially in those that are more challenging. A FT duration of more than 30 min has an adequate accuracy in identifying VARC-3 technical failure (TS and DS) and absence of VARC-2 ES, selecting patients who are likely to take advantage from more careful in-hospital follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Transcatheter aortic valve replacement (TAVR) is an almost totally cine-fluoroscopic guided procedure. The amount of radiation used during the procedure is strictly related to the fluoroscopy time (FT), that has already been demonstrated to be associated with outcomes and complexity of coronary procedures. The aim of our study is to demonstrate the relationship between FT and the short-term outcomes after TAVR defined by to the Valve Academic Research Consortium (VARC)-2 and -3 consensus documents.
METHODS
METHODS
After splitting 1797 consecutive patients into tertiles of FT, the composite endpoint early safety (ES) was adjudicated according to VARC-2 and VARC-3 definitions, whereas the composite endpoints device success (DS) and technical success (TS) according to VARC-3 criteria.
RESULTS
RESULTS
The absence of all these outcomes (VARC-2 ES amd VARC-3 TS, DS, and ES) was significantly associated with longer FT: this association was independent from both intraprocedural complications and other intraprocedural factors linked to longer FT, and still persisted after propensity score matching analysis. Notwithstanding, after receiver operating characteristic analysis, FT had adequate diagnostic accuracy in identifying the absence of only VARC-3 TS and VARC-2 ES.
CONCLUSION
CONCLUSIONS
Longer FT is related with periprocedural and short-term outcomes after the procedure, especially in those that are more challenging. A FT duration of more than 30 min has an adequate accuracy in identifying VARC-3 technical failure (TS and DS) and absence of VARC-2 ES, selecting patients who are likely to take advantage from more careful in-hospital follow-up.
Identifiants
pubmed: 37998517
pii: jcdd10110459
doi: 10.3390/jcdd10110459
pmc: PMC10671838
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Heart J. 2011 Jan;32(2):191-7
pubmed: 20843959
EuroIntervention. 2012 Oct;8(6):679-84
pubmed: 23086785
J Am Coll Cardiol. 2009 Jul 21;54(4):303-11
pubmed: 19608027
Int Heart J. 2021 Mar 30;62(2):282-289
pubmed: 33731534
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Eur Heart J. 2021 May 14;42(19):1825-1857
pubmed: 33871579
Br Med Bull. 2003;68:259-75
pubmed: 14757722
Catheter Cardiovasc Interv. 2015 Jun;85(7):1256-61
pubmed: 24399646
Radiology. 2022 Jul;304(1):4-17
pubmed: 35638923
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Coll Cardiol. 2015 May 26;65(20):2184-94
pubmed: 25787196
Circ Cardiovasc Interv. 2010 Aug;3(4):359-66
pubmed: 20606135
J Am Coll Cardiol. 2010 Mar 16;55(11):1080-90
pubmed: 20096533
Int J Cardiol. 2013 Sep 1;167(5):1945-52
pubmed: 22633667
Am J Cardiol. 2021 Jan 15;139:71-78
pubmed: 33190811
Eur Heart J. 2012 Oct;33(19):2403-18
pubmed: 23026477
J Cardiovasc Dev Dis. 2023 May 31;10(6):
pubmed: 37367409
Circ Cardiovasc Interv. 2008 Dec;1(3):167-75
pubmed: 20031675
J Clin Med. 2021 Oct 24;10(21):
pubmed: 34768430
Circulation. 2010 Jul 6;122(1):62-9
pubmed: 20566953
Circ Cardiovasc Interv. 2019 Jan;12(1):e006823
pubmed: 30599769
EuroIntervention. 2008 Aug;4(2):242-9
pubmed: 19110790
J Invasive Cardiol. 2007 May;19(5):208-13
pubmed: 17476034
JACC Cardiovasc Interv. 2023 Feb 27;16(4):396-411
pubmed: 36858659
Eur Heart J. 2011 Jan;32(2):148-57
pubmed: 21075775
J Clin Med. 2021 Apr 03;10(7):
pubmed: 33916666
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
Catheter Cardiovasc Interv. 2011 Mar 1;77(4):546-56
pubmed: 21254324